This clinical trial is designed to include two parts:~Part 1: Assessment of feasibility and safety of administering YM155 in combination with docetaxel and prednisone in subjects with hormone refractory prostate cancer (HRPC) [ ENROLLMENT COMPLETED ]~Part 2: Assessment of feasibility and safety of administering YM155 in combination with docetaxel in subjects with solid tumors (except HRPC).~This registration has been updated to reflect the design requirements of PART 2.
To determine the feasibility and safety of administering YM155 in combination with docetaxel